David joined MTI in 2003 to build its capabilities in the medical and healthcare arenas.
As a qualified doctor with a Harvard MBA and a rich background of industrial and academic business development and strategy expertise David has carved himself out to be one of the leaders in the field of UK university technology spinouts and investment. After senior roles at Glaxo and Roche, he headed up Imperial College’s spinout incubator and fund, worked for a venture backed cancer vaccines company and has now spent 13 years prosecuting a medtech investing strategy at MTI, whose highlights include ApaTech a bone graft materials company from London and Cambridge universities which was sold in 2010 to Baxter International for $300m.
As a key component of the team which raised the UMIP Premier Fund David led MTI's medical and healthcare activities until stepping down as General Partner in May 2016. However he continues to be available for ad hoc advice as a Venture Partner. He is now Head of Seed Funds at LifeArc (formerly Medical Research Council Technologies) and is also Senior Independent Director of the Worldwide Healthcare Trust plc.